Treatment with VCAM-LNPs containing IL-10 mRNA led to ~69% reduction in hematoma size at 72 hours after ICH and ~65% improvement in motor behavior in our model, with no improvement in vascular leakage. This evidence concerns the gene IL10 and hematoma.